Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations by Diana O. Perkins, Clark D. Jeffries, Scott R. Clark, Rachel Upthegrove, Cassandra M. J. Wannan, Naomi R. Wray, Qingqin S. Li, Kim Q. Do, Elaine Walker, G. Paul Amminger, Alan Anticevic, David Cotter, Lauren M. Ellman, David Mongan, Christina Phassouliotis, Jenna Barbee, Sharin Roth, Tashrif Billah, Cheryl Corcoran, Monica E. Calkins, Felecia Cerrato, Ines Khadimallah, Paul Klauser, Inge Winter-van Rossum, Angela R. Nunez, Rachel S. Bleggi, Alicia R. Martin, Sylvain Bouix, Ofer Pasternak, Jai L. Shah, Catherine Toben, Daniel H. Wolf, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Rene S. Kahn, John M. Kane, Patrick D. McGorry, Carrie E. Bearden, Barnaby Nelson, Martha E. Shenton, Scott W. Woods

Get full text